Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is China Resources Medical Holdings Co Debt-to-EBITDA?
China Resources Medical Holdings CoCMHDF 88 Debt-to-EBITDA is 1.75 as of Dec. 2025, which is 67% above its 10-year median of 1.05. GuruFocus rates CMHDF with a GF Score™ of 88/100 and a GF Value™ of $0.94. The stock has 5 warning signs investors should review. Among 478 Healthcare Providers & Services companies, China Resources Medical Holdings Co ranks better than 68.41% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CMHDF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.37 Med: 1.05 Max: 3.68
Current: 1.1
During the past 13 years, the highest Debt-to-EBITDA Ratio of China Resources Medical Holdings Co was 3.68. The lowest was 0.37. And the median was 1.05.
CMHDF's Debt-to-EBITDA is ranked better than 68.41% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs CMHDF: 1.10
China Resources Medical Holdings Co (OTCPK:CMHDF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China Resources Medical Holdings Co Debt-to-EBITDA Related Terms
China Resources Medical Holdings Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Medical Holdings Co Debt-to-EBITDA Chart
For the Medical Care Facilities subindustry, China Resources Medical Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Medical Holdings Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, China Resources Medical Holdings Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Resources Medical Holdings Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
China Resources Medical Holdings Co (CMHDF) has a Debt-to-EBITDA of 1.75 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Resources Medical Holdings Co. This is 67% above median its historical median of 1.05. Over the past decade, China Resources Medical Holdings Co's Debt-to-EBITDA has ranged from 0.37 to 3.68. According to the industry distribution chart, China Resources Medical Holdings Co ranks #151 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 31.6%.
Is China Resources Medical Holdings Co's Debt-to-EBITDA too high?
China Resources Medical Holdings Co's current Debt-to-EBITDA of 1.75 is 67% above median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 3.68. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. China Resources Medical Holdings Co's value of 1.75 is 22.2% below this industry median. Based on the distribution chart, China Resources Medical Holdings Co ranks #151 out of 478 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, China Resources Medical Holdings Co has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does China Resources Medical Holdings Co's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, China Resources Medical Holdings Co ranks #151 out of 478 companies for Debt-to-EBITDA. This puts China Resources Medical Holdings Co in the upper half of its industry. The industry median Debt-to-EBITDA is 2.25. China Resources Medical Holdings Co's value of 1.75 is 22.2% below this benchmark. Historically, China Resources Medical Holdings Co's own Debt-to-EBITDA has ranged from 0.37 to 3.68 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 2.25, China Resources Medical Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Medical Holdings Co's current Debt-to-EBITDA of 1.75 is 22.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Resources Medical Holdings Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Medical Holdings Co's current Debt-to-EBITDA is 1.75, which is 67% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Medical Holdings Co stock overvalued right now?
China Resources Medical Holdings Co (CMHDF) has a current Debt-to-EBITDA of 1.75. The stock's GF Value™ is $0.94, compared to a current price of $0.58 — trading 38.3% below its estimated fair value. The current Debt-to-EBITDA is 1.75, which is 67% above median its 10-year median of 1.05 and 22.2% below the Healthcare Providers & Services industry median of 2.25. China Resources Medical Holdings Co's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China Resources Medical Holdings Co (CMHDF), the current Debt-to-EBITDA is 1.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Medical Holdings Co (CMHDF) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Medical Holdings Co stock appears to be undervalued.
The current stock price of $0.58 is trading 38.3% below its estimated GF Value™ of $0.94.
Key valuation signals for CMHDF:
Debt-to-EBITDA: 1.75 (67% above median its 10-year median of 1.05)
GF Value™: $0.94 vs. price of $0.58 (38.3% below fair value)
Industry Position: 22.2% below the Healthcare Providers & Services median (#151 of 478)
No single metric tells the full story. See the CMHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Medical Holdings Co Business Description
China Resources Medical Holdings Co Ltd is engaged in the provision of general healthcare services; provision of hospital management services, sale of pharmaceuticals, medical devices, and medical consumables, and provision of other services in the Chinese Mainland. The group has two operating segments: Hospital Business and Other Business. The Hospital Business segment includes outpatient business and inpatient business corresponding to self-owned hospitals. The Other business segment includes operation management services, supply chain services, and other ancillary services provided to participating hospitals and IOT/OT hospitals. It generates the majority of its revenue from the Hospital Business segment.
88GF Score
Get the complete analysis for CMHDF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMHDF has been successfully added to your 
